CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump, Petro Discuss Sanctions and Strengthening U.S.–Colombia Relations After Oval Office Meeting 
U.S.–Iran Nuclear Talks Scheduled in Oman as Diplomatic Efforts Resume 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
India Services Sector Rebounds in January as New Business Gains Momentum: HSBC PMI Shows Growth 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Russia Prepares for Post–New START Era as U.S.-Russia Nuclear Arms Control Nears Collapse 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Japan’s Agricultural, Forestry and Fishery Exports Hit Record High in 2025 Despite Tariffs 
Japan Services Sector Records Fastest Growth in Nearly a Year as Private Activity Accelerates 
Trump Extends AGOA Trade Program for Africa Through 2026, Supporting Jobs and U.S.-Africa Trade 
Australia’s Corporate Regulator Urges Pension Funds to Boost Technology Investment as Industry Grows 
China Services PMI Hits Three-Month High as New Orders and Hiring Improve 
South Korea’s government pledged stronger support for key export industries, including biopharmaceuticals and automobiles, as sweeping U.S. tariffs under President Donald Trump loom. Acting Finance Minister Kim Beom-seok said Seoul would prepare measures for item-specific duties, particularly on pharmaceuticals and semiconductors, and expand support for reshoring or “U-turn” investments.
The U.S. has imposed 25% tariffs on various South Korean products, prompting Seoul to roll out support packages for affected sectors such as autos, chips, and small exporters. The government plans to introduce new aid programs for the biopharma industry once the U.S. finalizes tariff details. Trump’s recent executive order aims to fast-track pharmaceutical plant approvals and promote domestic drug manufacturing, increasing pressure on foreign suppliers.
South Korea exported $9.59 billion worth of pharmaceutical products in 2024, 16% of which went to the U.S., its largest market. Celltrion Chairman Seo Jung-jin noted the company is delaying decisions on U.S. contract manufacturing due to high local costs, though he expects minimal impact thanks to Celltrion’s price competitiveness. The U.S. accounts for nearly 30% of the firm’s revenue.
Meanwhile, the U.S. FDA is conducting a May 19–27 inspection of Samsung Biologics’ Incheon plant, although it's unclear if it’s linked to new U.S. policy changes. Samsung Biologics shares jumped over 5% in early Wednesday trade, while Celltrion rose 0.5%, helping lift the KOSPI index by 1.1%.
The government has already mobilized 28.6 trillion won ($20.6 billion) in support measures and is pushing to negotiate tariff exemptions with Washington by the July 8 deadline. Trade Minister Ahn Duk-geun said talks are ongoing but warned progress may be delayed due to South Korea’s June 3 snap presidential election.
